POVOFORTAY Film-coated tablet Ref.[117097] Active ingredients: Povorcitinib

Source: European Medicines Agency (EU)  Revision Year: 2026  Publisher: Incyte Biosciences Distribution B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands

4.1. Therapeutic indications

Povofortay is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults who have responded inadequately to, or who are intolerant or contraindicated to an anti-TNF therapy.

4.2. Posology and method of administration

Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of hidradenitis suppurativa.

Posology

The dose is 45 mg or 75 mg once daily based on individual patient characteristics:

  • A dose of 45 mg once daily is recommended for patients at higher risk of venous thromboembolism (VTE), major adverse cardiovascular events (MACE) and malignancy (see section 4.4).
  • A dose of 75 mg once daily may be appropriate for patients with high disease burden who are not at higher risk of VTE, MACE and malignancy (see section 4.4).
  • A dose of 75 mg once daily may also be appropriate for patients with an inadequate response to 45 mg once daily.
  • The lowest effective dose to maintain response should be used.

Consideration should be given to discontμία φορά την ημέραinuing treatment in patients who have shown no evidence of therapeutic benefit after 12 weeks of treatment. Patients with an initial partial response at week 12 may subsequently improve with continued treatment.

If retreatment with povorcitinib is indicated, the above guidance on dose and treatment duration should be followed.

Treatment initiation

Treatment with povorcitinib should not be initiated in patients with a platelet count <50 × 109/L, an absolute neutrophil count (ANC) <1 × 103/mm³, or who have a haemoglobin value <8 g/dL (see section 4.4).

Laboratory monitoring

Guidance for laboratory monitoring and dose initiation or interruption is provided in Table 1.

Table 1. Laboratory tests and monitoring guidance:

Laboratory testActionMonitoring
guidance
Complete blood count
including platelet count,
haemoglobin (Hb), and
absolute neutrophil count
(ANC)
Treatment should be interrupted if platelet
counts are <50 × 109/L. Treatment may be
restarted once platelet count returns above
this value.
Before treatment
initiation and
thereafter according
to individual patient
management.
Treatment should be interrupted if Hb is
<8 g/dL. Treatment may be restarted once
Hb returns above this value.
Treatment should be interrupted if ANC
<1 × 103/mm³. Treatment may be restarted
once neutrophil count returns above this
value.
μία φορά την ημέραLipidsPatients should be monitored according to
clinical guidelines for hyperlipidaemia.

Treatment interruption

If a patient develops a serious infection, treatment should be interrupted until the infection is controlled (see section 4.4).

Interruption of dosing may be needed for management of laboratory abnormalities as described in Table 1.

Missed doses

If a dose is missed, patients should be advised to take the dose as soon as possible unless it is less than 12 hours before the next dose, in which case the patient should not take the missed dose. Thereafter, dosing should be resumed at the regular scheduled time.

Interactions

For patients receiving chronic treatment with strong systemic CYP3A4 inhibitors, the recommended dose is 45 mg once daily (see section 4.5). Co-administration of povorcitinib with chronic use of strong systemic CYP3A4 inducers is not recommended (see section 4.5).

Special populations

Elderly

For patients 65 years of age and older, the recommended dose is 45 mg once daily (see section 4.4).

Renal impairment

No dose adjustment is required in patients with renal impairment, including patients with end stage renal disease (ESRD) (see section 5.2).

Hepatic impairment

No dose adjustment is required in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment (see section 5.2). For patients with severe (Child-Pugh C) hepatic impairment, the maximum recommended dose is 45 mg once daily (see section 5.2).

Paediatric population

There is no relevant use of povorcitinib in children under 12 years of age for the treatment of hidradenitis suppurativa.

The safety and efficacy of povorcitinib in children and adolescents between 12 and less than 18 years of age have not yet been established. No data are available.

Method of administration

For oral use.

Tablets can be taken with or without food. Tablets should be swallowed whole and should not be split, crushed or chewed.

4.9. Overdose

Povorcitinib was administered in clinical studies up to single oral doses of 450 mg once daily (6 times the recommended human dose of 75 mg once daily) and multiple oral doses up to 120 mg once daily for 10 days. Adverse reactions were comparable to those seen at lower doses and no specific toxicities were identified. Pharmacokinetics data in healthy adult participants indicate that more than 90% of the administrated dose up to 450 mg is expected to be eliminated after 5 days.

In the event of overdose, it is recommended that the patient be monitored for any signs and symptoms of adverse reactions (see section 4.8) and appropriate symptomatic treatment be instituted immediately.

6.3. Shelf life

2 years.

6.4. Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5. Nature and contents of container

PVC-PCTFE/Aluminium blister containing 14 film-coated tablets. Each carton contains 28 or 98 tablets.

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈